SecBot SecBot
SECBOTREPLAY Home › Report › GTBP

GTBP · GT Biopharma entered into an Investigator Initiated Clinical Trial…

GT Biopharma, Inc. · 8-K filed Apr 7, 2026 at 07:05 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Apr 7, 2026 at 07:05 ET

GT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota to sponsor a phase 1a/1b clinical trial of its drug candidate GTB-5550 for advanced solid tumors. The company will fund up to $3.8 million over three years for the study, which remains in the early research phase.

  • GT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota
  • The agreement supports a phase 1a/1b clinical trial of GTB-5550 for advanced solid tumors
  • GT Biopharma will fund up to $3.8 million over three years for the study
  • The trial is sponsored by the University of Minnesota, not GT Biopharma

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access